BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.92 CNY | +1.96% |
|
+11.85% | -10.47% |
| Apr. 02 | Tranche Update on Bloomage BioTechnology Corporation Limited's Equity Buyback Plan announced on August 17, 2023. | CI |
| Feb. 29 | Bloomage Biotech Names CFO | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 40,032 | 70,286 | 74,544 | 65,081 | 28,862 | 28,862 | - |
| Enterprise Value (EV) 1 | 40,032 | 70,286 | 72,968 | 63,812 | 32,239 | 27,715 | 26,958 |
| P/E ratio | 68.4 x | 108 x | 95.9 x | 67.3 x | 54.9 x | 33 x | 22.8 x |
| Yield | 0.44% | 0.28% | 0.32% | 0.45% | 0.91% | 1.02% | 1.28% |
| Capitalization / Revenue | 21.2 x | 26.7 x | 15.1 x | 10.2 x | 5.3 x | 3.85 x | 3.19 x |
| EV / Revenue | 21.2 x | 26.7 x | 14.7 x | 10 x | 5.3 x | 3.7 x | 2.98 x |
| EV / EBITDA | 53.1 x | 84.5 x | 70.6 x | 48.6 x | 24.1 x | 22 x | 16.4 x |
| EV / FCF | - | - | 148 x | -1,064 x | -19.4 x | - | - |
| FCF Yield | - | - | 0.67% | -0.09% | -5.14% | - | - |
| Price to Book | 8.8 x | 14 x | 13.1 x | 9.81 x | 4.67 x | 3.66 x | 3.22 x |
| Nbr of stocks (in thousands) | 480,000 | 480,000 | 480,000 | 481,085 | 481,678 | 481,678 | - |
| Reference price 2 | 83.40 | 146.4 | 155.3 | 135.3 | 59.92 | 59.92 | 59.92 |
| Announcement Date | 2/28/20 | 2/25/21 | 2/25/22 | 2/27/23 | 2/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,886 | 2,633 | 4,948 | 6,359 | 6,081 | 7,498 | 9,049 |
| EBITDA 1 | 753.7 | 832.1 | 1,033 | 1,314 | 1,147 | 1,258 | 1,644 |
| EBIT 1 | 699.6 | 757 | 905.6 | 1,136 | 705.4 | 1,138 | 1,479 |
| Operating Margin | 37.1% | 28.76% | 18.3% | 17.87% | 11.6% | 15.17% | 16.35% |
| Earnings before Tax (EBT) 1 | 584.6 | 758.9 | 890.2 | 1,136 | 698.9 | 1,222 | 1,508 |
| Net income 1 | 585.6 | 645.8 | 782.3 | 970.9 | 587.4 | 872.6 | 1,263 |
| Net margin | 31.06% | 24.53% | 15.81% | 15.27% | 9.66% | 11.64% | 13.96% |
| EPS 2 | 1.220 | 1.350 | 1.620 | 2.010 | 1.220 | 1.814 | 2.623 |
| Free Cash Flow 1 | - | - | 491.9 | -59.98 | -1,421 | - | - |
| FCF margin | - | - | 9.94% | -0.94% | -22.39% | - | - |
| FCF Conversion (EBITDA) | - | - | 47.62% | - | - | - | - |
| FCF Conversion (Net income) | - | - | 62.87% | - | - | - | - |
| Dividend per Share 2 | 0.3700 | 0.4100 | 0.4900 | 0.6100 | 0.5426 | 0.6102 | 0.7656 |
| Announcement Date | 2/28/20 | 2/25/21 | 2/25/22 | 2/27/23 | 2/28/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,160 | 1,937 | 1,076 | 1,936 | - | 1,681 | 1,385 | 2,039 | 3,424 | 1,305 | 1,770 | 3,076 | 1,146 | 1,691 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | 230.1 | - | 162.3 | 258.2 | - | 338.1 | 242.5 | 313.8 | 556.3 | 243.1 | 274.5 | - | 93.55 | - | - | - | - | - |
| Operating Margin | 19.84% | - | 15.09% | 13.34% | - | 20.12% | 17.51% | 15.39% | 16.25% | 18.63% | 15.5% | - | 8.16% | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 208.2 | 360.6 | 194.7 | 227 | - | - | - | 293.5 | 497.7 | - | 224.1 | 424.6 | 89.79 | 667.8 | - | - | - | - |
| Net margin | 17.95% | 18.62% | 18.11% | 11.73% | - | - | - | 14.39% | 14.54% | - | 12.66% | 13.81% | 7.84% | 39.48% | - | - | - | - |
| EPS 2 | 0.4300 | - | 0.4000 | 0.4700 | - | 0.5600 | 0.4300 | 0.6000 | - | 0.4200 | 0.4600 | - | 0.1900 | 0.8906 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.5422 | - | - |
| Announcement Date | 8/30/21 | 8/30/21 | 10/26/21 | 2/25/22 | 4/25/22 | 7/20/22 | 10/28/22 | 2/27/23 | 2/27/23 | 4/28/23 | 8/29/23 | 8/29/23 | 10/30/23 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 1,576 | 1,269 | 1,234 | 1,147 | 1,904 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 492 | -60 | -1,421 | - | - |
| ROE (net income / shareholders' equity) | 18.7% | 13.5% | 14.6% | 15.8% | 8.26% | 12.9% | 14.5% |
| ROA (Net income/ Total Assets) | 16.6% | 12.1% | 11.8% | 12% | 6.86% | 9.93% | 10.5% |
| Assets 1 | 3,521 | 5,344 | 6,610 | 8,093 | 8,568 | 8,791 | 12,061 |
| Book Value Per Share 2 | 9.480 | 10.50 | 11.90 | 13.80 | 14.30 | 16.40 | 18.60 |
| Cash Flow per Share 2 | 0.7600 | 1.470 | 2.640 | 1.320 | 2.560 | 2.660 | 3.360 |
| Capex 1 | 450 | 763 | 784 | 695 | 672 | 312 | 455 |
| Capex / Sales | 23.88% | 28.97% | 15.85% | 10.93% | 10.58% | 4.16% | 5.03% |
| Announcement Date | 2/28/20 | 2/25/21 | 2/25/22 | 2/27/23 | 2/28/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
59.92
CNY
Average target price
83.72
CNY
Spread / Average Target
+39.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.47% | 3.98B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 688363 Stock
- Financials Bloomage BioTechnology Corporation Limited
